Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 3/20 | 0.37 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.37 |
| ▸ | CHRNG | P07510 | 3/20 | 0.37 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.37 |
| ▸ | CHRND | Q07001 | 3/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12666244 | 0.97 | CES2 (0.42) | TSHRRECQLPAOXALDH1A1CES2 | |
| SCHEMBL24393831 | 0.94 | CES2 (0.39) | TSHRRECQLPAOXALDH1A1CES2 | |
| SCHEMBL28994410 | 0.86 | TSHR (0.41) | TSHRRECQLPAOXALDH1A1TLR2 | |
| SCHEMBL13034763 | 0.86 | TSHR (0.43) | TSHRRECQLALDH1A1CES2TLR2 | |
| SCHEMBL16182412 | 0.86 | TSHR (0.56) | TSHRRECQLALDH1A1CES2FAAH | |
| SCHEMBL1891419 | 0.86 | TSHR (0.43) | TSHRRECQLALDH1A1TLR2CHRNA1 | |
| SCHEMBL23841224 | 0.84 | TSHR (0.39) | TSHRRECQLPAOXALDH1A1TLR2 | |
| SCHEMBL12666247 | 0.84 | MEN1 (0.40) | TSHRRECQLCES2TLR2FAAH | |
| SCHEMBL12666251 | 0.84 | MEN1 (0.40) | TSHRRECQLCES2TLR2FAAH | |
| SCHEMBL13996629 | 0.84 | TSHR (0.43) | TSHRRECQLALDH1A1TLR2CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010614-B2 | Derivatives of GLP-1 like peptides, and uses thereof | NOVO NORDISK A/S (DK) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010614-B2 | Derivatives of GLP-1 like peptides, and uses thereof | GLP1R, GIPR, IAPP | TSHR 471/4885RECQL 4283/4885PAOX 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.